SS
SGMO

Steve Schonfeld’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Steve Schonfeld’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-31,425
Closed -$20.6K – 2484
2025
Q1 		$20.6K Sell
31,425
-1,678,190
-98% -$1.78M ﹤0.01% 2104
2024
Q4 		$1.74M Buy
+1,709,615
New +$3.13M 0.01% 888
2024
Q3 		– Sell
-94,700
Closed -$33.9K – 2381
2024
Q2 		$33.9K Sell
94,700
-350,600
-79% -$189K ﹤0.01% 1972
2024
Q1 		$298K Buy
+445,300
New +$323K ﹤0.01% 1648

Other funds holding SGMO

YAG
Yorkville Advisors Global Mountainside, New Jersey $86.2M AUM 41.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Steve Schonfeld's SGMO Position: Q2 2025 in Review

Steve Schonfeld sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q2 2025, closing a stake of 31,425 shares — an estimated $20.6K sold.

Steve Schonfeld first reported a position in SGMO in Q1 2024 and held it in 4 quarters. The position peaked at $1.74M in Q4 2024. 114 funds tracked by Wall St. Rank hold SGMO as of Q2 2025.

  • Steve Schonfeld reported no remaining SANGAMO THERAPEUTICS INC position as of Q2 2025 after selling out during the quarter.
  • Steve Schonfeld sold 31,425 SANGAMO THERAPEUTICS INC shares in Q2 2025, an estimated $20.6K.
  • Steve Schonfeld first reported a position in SANGAMO THERAPEUTICS INC in Q1 2024 and held it in 4 quarters.
  • Steve Schonfeld's SANGAMO THERAPEUTICS INC position peaked at $1.74M in Q4 2024.
  • 114 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q2 2025.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.